- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Relapsing-remitting multiple sclerosis
- Meeting Date: March 2023
- Public Summary Document (PSD) March 2023 PBAC Meeting - (PDF 370KB)
- Public Summary Document (PSD) March 2023 PBAC Meeting - (Word 59KB)
Natalizumab – March 2023
Natalizumab: Injection 150 mg in 1 mL single dose pre-filled syringe; Tysabri®
Last updated
30 June 2023